Wuhan Institute of Biological Products Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 1990-03-08
- Employees
- -
- Market Cap
- -
- Website
- http://www.wibp.com.cn
Clinical Study of F61 Injection in Healthy Chinese Subjects
Phase 1
- Conditions
- COVID-19
- Interventions
- Drug: F61 injectionDrug: F61 Placebo
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Wuhan Institute of Biological Products Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT05483504
To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years
Phase 4
- Conditions
- Influenza
- Interventions
- Biological: Inavtivated Quadrivalent Influenza Virus Split Vaccine
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Wuhan Institute of Biological Products Co., Ltd
- Target Recruit Count
- 360
- Registration Number
- NCT05389137
- Locations
- 🇨🇳
Yangchun Center for Disease Control and Prevention, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19
Phase 2
- Conditions
- COVID-19
- Interventions
- Biological: DXP604
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Wuhan Institute of Biological Products Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT05381519
© Copyright 2025. All Rights Reserved by MedPath